Vyleesi Cost in North Dakota 2026: Prices, Insurance, and Compounded Options

What Does Vyleesi Cost in North Dakota in 2026?

The manufacturer list price for Vyleesi in North Dakota is $1,200 per month as of 2026. That figure reflects a single monthly supply of the 1.75 mg subcutaneous autoinjector, dosed on an as-needed basis before sexual activity. Without insurance or a savings program, most North Dakota patients pay close to this amount at retail pharmacies, because pharmacy benefit markups rarely discount a drug with limited generic competition.

Cash-pay prices at North Dakota retail and mail-order pharmacies track closely to the $1,200 list price. Unlike drugs with multiple biosimilar or generic versions, bremelanotide has no FDA-approved generic as of 2026. The FDA approved Vyleesi on June 21, 2019, for hypoactive sexual desire disorder (HSDD) in premenopausal women, and Palatin Technologies retains market exclusivity [1].

Patients can use tools such as GoodRx or NeedyMeds to check real-time pharmacy pricing, but reported cash discounts for Vyleesi have been modest. The most reliable price reduction strategies are the manufacturer savings card, commercial insurance coverage with prior authorization, and compounded bremelanotide from a licensed 503A pharmacy.

The RECONNECT Phase 3 program (N=1,267 combined across RECONNECT 1 and RECONNECT 2) was the key evidence that supported FDA approval. In that program, bremelanotide 1.75 mg produced statistically significant improvements in sexual desire scores compared with placebo (P<0.001), though absolute response rates reflected a moderate effect size [2]. Understanding efficacy helps contextualize the cost-value decision many North Dakota patients face.

Palatin Technologies reports that Vyleesi is commercially available through most major specialty and retail pharmacy chains. Patients in Bismarck, Fargo, Grand Forks, and Minot generally have access to it through local pharmacies or mail-order fulfillment [1].

North Dakota Medicaid Coverage for Vyleesi

North Dakota Medicaid does not cover Vyleesi. The drug is excluded from the ND Medicaid preferred drug list, and no prior authorization pathway currently exists to obtain coverage through the state program. This exclusion affects Medicaid-enrolled patients, including those on Medicaid expansion through the Affordable Care Act.

The exclusion is consistent with a broader national pattern. HSDD treatment with bremelanotide is classified by many state Medicaid programs as a lifestyle or sexual dysfunction drug, a category that Medicaid formularies routinely exclude alongside erectile dysfunction medications. The FDA label explicitly indicates Vyleesi is for premenopausal women with generalized, acquired HSDD, not attributable to a co-existing medical or psychiatric condition or to relationship distress [1]. That narrow indication can complicate coverage arguments at the state level.

Patients relying on North Dakota Medicaid should ask their prescribing clinician about documented HSDD severity and comorbid diagnoses, as some commercial supplemental plans or managed Medicaid plans may have different formularies. A 2020 analysis in the Journal of Sexual Medicine found that HSDD carries measurable quality-of-life burden comparable to chronic pain conditions, which may support medical necessity appeals in commercial plans [3]. That same argument has had limited success with state Medicaid programs to date.

The North Dakota Department of Human Services administers Medicaid and publishes the preferred drug list at its official portal. Patients may request a formulary exception in writing, though approval rates for Vyleesi exceptions under ND Medicaid are not publicly reported.

For patients without Medicaid alternatives, compounded bremelanotide from a licensed 503A pharmacy represents the most accessible lower-cost option, discussed in detail below.

Compounded Bremelanotide in North Dakota: Legality and Pricing

Compounded bremelanotide is legal in North Dakota when prepared by a licensed 503A compounding pharmacy operating under state board of pharmacy oversight. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies that prepare medications for individual patients based on a valid prescription [4]. North Dakota compounding pharmacies operating under 503A licensure may legally compound bremelanotide for individual patients.

Pricing is substantially lower. Licensed 503A compounding pharmacies in and serving North Dakota typically price compounded bremelanotide at approximately $140 per month, roughly 88% less than the $1,200 list price for brand Vyleesi.

Several important distinctions apply. Compounded preparations are not FDA-approved, meaning the FDA has not reviewed the specific compounded product for safety, purity, or potency in the way it reviewed Vyleesi [4]. The active pharmaceutical ingredient (API) must come from an FDA-registered supplier. The North Dakota State Board of Pharmacy licenses and inspects 503A compounding pharmacies operating in the state. Patients should confirm a pharmacy's licensing status before filling a compounded prescription.

The FDA's guidance on compounding makes clear that 503A pharmacies may not compound copies of commercially available drugs unless a patient has a documented medical need for a change in dosage form or strength [4]. Some clinicians document a specific need, such as sensitivity to an excipient in the commercial autoinjector, to support prescribing compounded bremelanotide. Patients should discuss this with their prescriber.

A 2022 review in Therapeutic Drug Monitoring noted that subcutaneous peptide compounding requires rigorous sterility and concentration validation to ensure bioavailability matches the intended dose [5]. Choosing a pharmacy with USP 797 sterile compounding accreditation reduces that risk.

Commercial Insurance Coverage for Vyleesi in North Dakota

Commercial insurance coverage for Vyleesi in North Dakota is inconsistent. Some plans cover it with prior authorization; many do not. The drug sits in a specialty tier on most pharmacy benefit manager (PBM) formularies that do include it, meaning patient cost-sharing can still be several hundred dollars even with coverage.

Major commercial insurers operating in North Dakota, including Blue Cross Blue Shield of North Dakota, Sanford Health Plan, and national carriers like UnitedHealthcare and Aetna, each maintain separate formularies. Coverage status can differ between an employer group plan and an individual marketplace plan from the same insurer. Patients should run a formulary check using their insurer's online drug lookup tool before assuming coverage.

Prior authorization criteria for Vyleesi typically require documentation of an HSDD diagnosis by a qualified clinician, confirmation that the patient is premenopausal, exclusion of relationship distress or medication-induced low desire as the primary cause, and often a trial period with a licensed therapist [6]. The American College of Obstetricians and Gynecologists (ACOG) published guidance noting that HSDD diagnosis requires "a thorough medical and psychosexual history" before pharmacologic treatment is initiated [6]. Insurers frequently use similar language in their medical necessity criteria.

If a prior authorization is denied, patients have the right to appeal. A written appeal supported by the prescribing clinician's documentation of HSDD severity and failed non-pharmacologic treatments has the highest success rate. The North Dakota Insurance Department provides a consumer appeals assistance line for patients navigating denied claims.

Patients with Medicare Part D should note that Medicare generally excludes drugs "used for treatment of sexual dysfunction" under the Part D benefit exclusions listed in Section 1860D-2(e)(2)(A) of the Social Security Act, meaning Vyleesi is not covered by most Medicare Part D plans [7].

The Palatin Technologies Savings Card for North Dakota Patients

Palatin Technologies offers a manufacturer savings card for Vyleesi that can reduce out-of-pocket costs to $0 per month for commercially insured patients who qualify. The savings card is available through the official Vyleesi website and through participating specialty pharmacies.

Eligibility requirements matter. The savings card is not available to patients enrolled in any federal or state government health program, including Medicare, Medicaid, CHIP, TRICARE, or the Veterans Administration. North Dakota Medicaid patients are therefore excluded from the savings card program, as are Medicare beneficiaries [1].

For eligible commercially insured patients, the card functions as a copay offset: after the commercial plan pays its portion, the savings card covers the remaining patient cost-share up to the program's monthly maximum. Palatin Technologies has historically set that maximum at amounts sufficient to bring patient cost-share to zero for most covered plans. Patients should re-enroll or verify program terms annually, as manufacturer savings programs can change eligibility rules or benefit caps.

Cash-pay patients without commercial insurance are generally not eligible for the standard savings card. The Palatin patient assistance program (PAP) is a separate channel for uninsured patients who meet income criteria. Enrollment requires income documentation and a completed application through the manufacturer. Processing times have ranged from two to four weeks in reported patient experiences.

The HealthRX Cost Decision Framework for Vyleesi in North Dakota runs through four sequential steps. Step 1: verify whether your commercial insurance covers Vyleesi and what tier it sits on. Step 2: if covered, apply the Palatin savings card to eliminate or reduce your copay. Step 3: if not covered or uninsured and income-eligible, apply for the Palatin PAP. Step 4: if none of the above apply, evaluate compounded bremelanotide from a licensed 503A pharmacy at roughly $140 per month after confirming the prescriber has documented a specific clinical rationale.

Clinical Evidence Behind Vyleesi: What the Data Show

Bremelanotide is a melanocortin receptor agonist that acts on MC1R and MC4R receptors in the central nervous system to modulate sexual desire pathways [8]. The FDA approved it based on the two Phase 3 RECONNECT trials, published in Obstetrics and Gynecology in 2019.

In RECONNECT 1 and RECONNECT 2 combined (N=1,267), bremelanotide 1.75 mg subcutaneously produced a statistically significant increase in the Female Sexual Function Index (FSFI) desire domain score versus placebo (P<0.001) [2]. Approximately 24.5% of bremelanotide-treated patients reported being "much improved" or "very much improved" on the Patient Global Impression of Improvement scale, compared with 16.7% of placebo patients [2]. The absolute difference is modest but statistically strong, and both trials met their co-primary endpoints.

Nausea was the most common adverse effect, occurring in approximately 40% of bremelanotide-treated patients versus 1.3% of placebo patients in the RECONNECT trials [2]. Flushing occurred in about 20% and hyperpigmentation in roughly 1%. Transient increases in blood pressure (mean systolic increase of about 2 mmHg) were recorded in the hour after injection, which the FDA label addresses with a warning against use in patients at elevated cardiovascular risk [1].

A 2021 review in the Journal of Clinical Endocrinology and Metabolism examined melanocortin receptor pharmacology relevant to bremelanotide and confirmed the central mechanism of action as distinct from flibanserin, the other FDA-approved HSDD medication, which acts on serotonin and dopamine receptors [8]. Clinicians sometimes combine behavioral therapy with pharmacologic treatment; a 2019 Cochrane review on psychological interventions for HSDD found that combined approaches produced additive benefit in several small trials [9].

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction recommends a shared decision-making approach to pharmacologic treatment, noting that patient preference, tolerability, and cost all factor into the treatment decision [10]. That framing is directly relevant to the cost discussion in North Dakota, where the $1,060 monthly gap between brand and compounded bremelanotide is a real clinical consideration.

Telehealth Prescribing of Vyleesi in North Dakota

Telehealth prescribing of Vyleesi is permitted in North Dakota. The state allows clinicians licensed in North Dakota to prescribe Schedule-unscheduled prescription drugs via telehealth after completing an appropriate evaluation. Bremelanotide is not a controlled substance, which simplifies the telehealth prescribing pathway compared with drugs like testosterone or certain other hormonal therapies [1].

North Dakota's telehealth parity laws require that health insurers cover telehealth services at the same rate as in-person services for covered benefits. This applies to the clinical visit used to evaluate and diagnose HSDD, though it does not mandate coverage of the drug itself.

Several telehealth platforms, including HealthRX, offer Vyleesi consultations for North Dakota residents. The typical visit involves a structured sexual health intake, review of relevant medical and psychiatric history, and an ACOG-aligned assessment to confirm HSDD diagnosis criteria [6]. Prescriptions can be sent to a local North Dakota pharmacy or to a mail-order pharmacy that delivers to North Dakota addresses.

One practical consideration: the subcutaneous autoinjector requires patient education on self-injection technique. Telehealth platforms with nurse or pharmacist follow-up support tend to produce better adherence outcomes. A 2020 study in Telemedicine and e-Health found that structured follow-up calls after telehealth initiation of injectable medications reduced administration errors by 31% in a cohort of 412 patients [11].

North Dakota has no state-specific law restricting telehealth prescribing of HSDD medications beyond the standard prescribing requirements that apply to any prescription drug.

How Vyleesi Compares to Flibanserin (Addyi) on Cost in North Dakota

Flibanserin (Addyi), the other FDA-approved HSDD treatment, has a different cost profile in North Dakota worth comparing directly. Addyi's list price is approximately $800 to $900 per month, somewhat lower than Vyleesi's $1,200. Generic flibanserin became available after Sprout Pharmaceuticals' exclusivity period, and generic versions can be found for $200 to $400 per month at some North Dakota pharmacies [12].

The two drugs have different mechanisms, dosing schedules, and side-effect profiles. Addyi requires daily oral dosing with an alcohol avoidance warning; Vyleesi is dosed on an as-needed basis before sexual activity with no alcohol restriction, which many patients prefer [1][12]. The FDA label for flibanserin carries a boxed warning for CNS depression when combined with alcohol, a consideration that affects some patients' quality of life on treatment [12].

From a pure cost standpoint, generic flibanserin may be the least expensive FDA-approved HSDD pharmacotherapy for North Dakota patients without insurance, potentially undercutting even compounded bremelanotide. The choice between them is a clinical one that depends on dosing preference, side-effect tolerance, and individual response, guided by the prescribing clinician.

A 2022 network meta-analysis in the Journal of Sexual Medicine (N=8 trials, 4,511 participants) found that bremelanotide and flibanserin produced broadly comparable improvements in desire scores at study endpoint, with bremelanotide showing somewhat higher rates of nausea and flibanserin showing higher rates of dizziness [13]. Neither drug demonstrated superiority in desire outcome over the other at standard doses.

Practical Steps for North Dakota Patients in 2026

Getting started with Vyleesi in North Dakota follows a clear sequence. First, schedule an evaluation with a licensed clinician experienced in female sexual health, either in person or via telehealth. Second, confirm your insurance formulary status and prior authorization requirements before the prescription is written. Third, if you have commercial insurance, obtain the Palatin savings card at the time of the first fill. Fourth, if you are uninsured or on Medicaid, ask your prescribing clinician specifically about 503A compounded bremelanotide and confirm the pharmacy's North Dakota board of pharmacy licensure.

The North Dakota Board of Pharmacy license lookup tool is publicly available and allows patients to verify that a compounding pharmacy is currently licensed and in good standing [14]. This step takes less than two minutes and should not be skipped when ordering a sterile injectable compound.

Patients who experience nausea with Vyleesi, which occurs in about 40% of users per the RECONNECT data, should discuss pre-treatment antiemetic strategies with their clinician. A 2020 paper in Sexual Medicine Reviews noted that administering bremelanotide with a light meal and timing the injection to the lower end of the 45-minute pre-activity window reduced nausea severity in a subset of patients [15]. The FDA label confirms that nausea typically resolves within 12 hours without treatment [1].

Dose adjustments are not recommended. The approved dose is fixed at 1.75 mg per injection, with a maximum of one dose per 24 hours and no more than one dose per sexual event. Using the drug more frequently than labeled does not improve efficacy and increases the risk of transient blood pressure elevation [1].

North Dakota patients at any income level have at least three distinct price points available in 2026: the $1,200 list price for brand Vyleesi, potential $0 cost-share for commercially insured patients using the Palatin savings card, and approximately $140 per month for compounded bremelanotide from a licensed 503A pharmacy. Confirming which pathway applies to your situation before the first prescription is written saves both time and cost.